Analytical Data
-
Gene name
MAGEB1
- Application
-
Alternative Names
MAGEL1; MAGE-Xp; DAM10; CT3.1; DSS/AHC Critical Interval MAGE Superfamily 10; Cancer/Testis Antigen Family 3, Member 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43366
-
Expression Region
Met1~Met347
-
Molecular Weight
50kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEB1 (Melanoma Antigen Gene B1) is a member of the MAGE family of proteins, which are primarily expressed in tumor cells and are considered potential targets for cancer immunotherapy. The research surrounding MAGEB1 has gained momentum due to its involvement in tumorigenesis and potential role as a tumor-associated antigen. It is predominantly expressed in various cancers, including melanoma and other solid tumors, making it a subject of interest for therapeutic interventions. Recent studies have focused on the characterization of MAGEB1 recombinant proteins, which facilitate the understanding of its structure, function, and immunogenic properties. By producing and analyzing these recombinant proteins, researchers aim to elucidate the role of MAGEB1 in cancer progression, the immune response, and its potential as a biomarker for diagnosis and prognosis. Furthermore, the development of MAGEB1-based vaccines and monoclonal antibodies holds promise for enhancing targeted cancer therapies, ultimately contributing to more effective treatment strategies in oncology. Understanding the molecular mechanisms underpinning MAGEB1 expression and its interaction with the immune system remains critical for the advancement of personalized cancer immunotherapy.
